The 2026 universal definition gives clinicians a shared framework for recognizing and documenting heart failure across emergency, outpatient and inpatient care. The change may affect referrals, documentation, coding workflows and research criteria, but health systems will still need clear local rules for applying the definition in practice.

What the revised definition changes

The Second Universal Definition of Heart Failure provides common terminology for a syndrome that is often recognized differently in emergency departments, ambulatory clinics, hospital units and administrative data. Its practical aim is consistency: a heart failure diagnosis should reflect the clinical syndrome and supporting cardiac or congestion evidence, not an isolated symptom, ejection fraction or billing label.

That distinction matters because dyspnea, edema, fatigue and exercise intolerance are nonspecific. Ejection fraction also describes a phenotype rather than establishing the syndrome on its own. The consensus framework instead calls for clinicians to integrate the presentation with objective evidence, which may include structural or functional cardiac abnormalities, natriuretic peptide results, imaging, hemodynamic findings or documented pulmonary or systemic congestion, as applicable to the clinical context.

The update should not be read as a single-test rule. Natriuretic peptide concentrations can be influenced by age, kidney function, atrial fibrillation, obesity and treatment, while imaging findings depend on timing, technique and loading conditions. A value or finding that supports heart failure in one patient may require a different interpretation in another.

The definition also separates several concepts that are commonly conflated. Heart failure is the clinical syndrome; left ventricular ejection fraction helps characterize phenotype; acute or chronic describes presentation and course; and severity or stage conveys progression and treatment needs. Keeping those elements distinct could reduce ambiguous referrals such as “low EF” without a documented syndrome or “possible CHF” carried indefinitely after an uncertain emergency visit.

How the consensus evidence should be read

This was a consensus definition update, not a randomized trial, diagnostic-accuracy cohort or treatment study. There was no enrolled patient population, comparator arm, prespecified follow-up period or intervention effect estimate. Consequently, the document cannot establish that adopting its terminology will reduce mortality, readmissions, diagnostic error or costs.

Its contribution is definitional and operational. The expert group evaluated the existing heart failure framework and proposed language intended for use across clinical practice, research and health systems. The update follows the first universal definition published in 2021 and should be interpreted alongside contemporary US heart failure guidance, which addresses diagnostic evaluation, staging and treatment but serves a different purpose.

That distinction is important for implementation committees. A consensus definition can establish what clinicians mean by heart failure, but it does not automatically specify an electronic phenotype, an International Classification of Diseases code, a quality-measure denominator or a trial inclusion criterion. Those uses require separate operational definitions, validation and governance.

Applying the definition across the care pathway

Emergency clinicians often work before all confirmatory information is available. The immediate record can distinguish a suspected syndrome from a confirmed diagnosis and document the evidence available at the time: symptoms and signs, imaging, natriuretic peptide testing, electrocardiography, prior cardiac history, competing diagnoses and response to treatment. Improvement after a diuretic may support the assessment, but treatment response alone is not specific enough to define heart failure.

In outpatient care, the main task is diagnostic reconciliation. A clinician reviewing an emergency or hospital label can determine whether objective findings supported heart failure, whether an alternative explanation became more likely and whether the condition remains clinically relevant despite symptom improvement. The longitudinal record is also the best place to preserve prior ventricular function and trajectory; a later normal or improved ejection fraction does not necessarily erase a well-supported history of heart failure.

For inpatient teams, the definition creates a documentation question as well as a diagnostic one. Notes should make clear whether heart failure was present, whether it was acute, chronic or acutely worsened, and which phenotype and objective findings support that conclusion. This is more useful than repeatedly copying a broad problem-list label. It also helps the next setting understand whether congestion resolved, whether diagnostic uncertainty remains and which findings need follow-up.

Care setting	Immediate implementation question	Documentation priority
Emergency department	Is heart failure confirmed, suspected or one of several competing diagnoses?	Record the syndrome, objective support and important alternatives
Outpatient clinic	Does a prior label meet the shared definition, and is the phenotype or trajectory current?	Reconcile prior imaging, biomarkers, congestion and clinical course
Inpatient service	What type and time course of heart failure affected this admission?	Link acuity and phenotype to the evidence supporting the diagnosis
Transition or referral team	What information must follow the patient for the diagnosis to remain interpretable?	Transfer key results, uncertainty, prior function and pending evaluation

Referral pathways may need parallel review. If access to a heart failure clinic currently depends only on an ejection-fraction threshold, the pathway may exclude patients with a preserved ejection fraction and a supported syndrome. Conversely, automatic referral based on a problem-list code can overwhelm specialty services with unverified diagnoses. A two-step process—clinical definition first, service-specific prioritization second—can preserve a common diagnosis while allowing referral criteria to reflect capacity and clinical urgency.

Coding, research and quality programs

The consensus document does not replace US coding rules. Clinicians establish and document the diagnosis; coding professionals apply the applicable ICD-10-CM conventions and organizational policies. A health system should therefore avoid silently converting every mention of edema, elevated natriuretic peptide or reduced ejection fraction into heart failure. It should also avoid assuming that adoption of the definition automatically changes reimbursement or reporting requirements.

Research teams face a related problem. Eligibility criteria may use ejection fraction, symptoms, natriuretic peptide thresholds, prior hospitalization or structural findings in combinations designed for a particular question. A participant can satisfy the universal clinical definition yet fail a trial-specific criterion, or meet an electronic screening rule that still requires adjudication. Protocols should state whether the 2026 definition is being used for screening, final eligibility, subgroup classification or endpoint adjudication.

Quality programs should likewise preserve the specifications under which performance is measured. Changing a heart failure denominator can alter apparent admission, readmission or treatment rates without any underlying change in care. Before comparing results over time, programs need a documented crosswalk between the former and revised definitions, version control for electronic logic, and testing for differential effects across age, sex, race, kidney function, obesity and care setting.

Limitations and unresolved implementation issues

Consensus methods depend on expert interpretation and the evidence available when the document was developed. The publication does not provide prospective validation showing how reliably different clinicians will apply the revised definition or how it will perform when translated into billing data, registries or electronic health record algorithms. Generalizability may also vary where echocardiography, natriuretic peptide testing or specialist review is less accessible.

The update therefore supports shared language, not automatic downstream decisions. Health systems still need to define who adjudicates uncertain cases, how historical diagnoses are retained or retired, which objective findings can populate structured fields, and when a revised label takes effect in clinical decision support. Prospective audits should examine agreement between settings, reclassification rates and unintended changes in referrals or quality denominators.

Questions clinicians ask

Does an elevated natriuretic peptide establish heart failure?

No. Natriuretic peptides can support the diagnosis, but they must be interpreted with symptoms, signs, cardiac findings and competing explanations. Kidney dysfunction, atrial fibrillation and age can raise concentrations, while obesity and prior treatment can produce lower values than expected.

Should a patient with improved ejection fraction lose the diagnosis?

Not automatically. A current ejection fraction describes present ventricular function, whereas the longitudinal diagnosis depends on the documented clinical history and prior objective evidence. Removing the label solely because function improved can obscure trajectory, previous risk and the rationale for ongoing management.

Can the 2026 definition be used directly for ICD-10-CM coding?

The definition can improve diagnostic documentation, but it is not itself a coding instruction. Coding must follow current US conventions and payer or institutional requirements, with the clinician documenting the supported diagnosis, acuity and phenotype rather than expecting an algorithm to infer them from isolated results.

Must research and quality programs adopt it immediately?

No. Each program should determine whether the revised definition fits its scientific or measurement purpose, then update specifications prospectively. Eligibility rules, endpoint definitions and performance denominators should be versioned and validated before new and historical results are compared.